Prevalence and risk factors of primary headache disorders among Healthcare professionals in México, results of a multicenter survey (P11-12.010)

Abstract

<h3>Objective:</h3> The objectives of this study were (1) to assess the prevalence of primary headaches among medical staff and nurses in México; (2) to describe risk factors for Tensional Headache and Migraine; (3) to examine the frequency of Medication-overuse headache (MOH). <h3>Background:</h3> The global prevalence of current headache disorders among adults is nearly 47%. A Mexican cohort in teachers reported a lifetime prevalence of 19% of migraine. Nevertheless, there is lack of epidemiology reports of other primary headache types in México. <h3>Design/Methods:</h3> An online survey was conducted randomly, including staff from 7 hospital centers, in the period from August 16 to 22, 2022. <h3>Results:</h3> Of a total of 387 surveys (attending physicians=63; residents=211; last year medical students=44; nursing staff=69), 324 (83.7%) stated they had headache, of which 239 (73.8%) had migraine and 253 (78.1%) tension headache. Headache was significantly more prevalent in nursing staff and last year medical students vs. residents and attendings (95.2%, 93.2% vs. 77.7%, 84.1%; P= 0.001), however, this difference was not observed in migraine-specific prevalence (77.3%, 78% VS 75.6%, 60.4; P=0.090) nor for tension headache (69.6%, 68.3% VS 82.3%, 83.0%; P=0.058). Medication abuse was found in 5.1%, being more frequent in nursing staff and last year medical students VS residents and assigned (7.6%, 14.6% VS 4.9%, 0.0%; P=0.022). No relationship was found for the onset or worsening of headache with the COVID-19 pandemic. <h3>Conclusions:</h3> In this first Mexican study of headache in healthcare professionals, it is confirmed that primary headaches are more prevalent than in the general population. <b>Disclosure:</b> Dr. Roman Guzman has nothing to disclose. Dr. Rodriguez-Leyva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Rodriguez-Leyva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva . Dr. Rodriguez-Leyva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Rodriguez-Leyva has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Lilly Eli and Company. Dr. Rodriguez-Leyva has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Torrent Pharmaceuticals Mexico. Dr. Rodriguez-Leyva has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for abbvie allergan. Dr. Aguilera Barragán Pickens has nothing to disclose. Ms. Badial has nothing to disclose. Dr. Vega has nothing to disclose.